When investors think of biotech stocks, the word “lottery” comes to mind. And for the most part, they are right. The vast bulk of the sector made up of smaller, early-stage drug developers with only one, or maybe two, new therapies in development. These firms live or die by how one drug performs. Fail the first round of a clinical trial and the stock is done for. Make it past the FDA’s watch and the stock soars.
A “lottery ticket” is certainly an accurate comparison when it comes to investing in biotech.